JP6051164B2 - 心肺バイパス用プライミング液 - Google Patents

心肺バイパス用プライミング液 Download PDF

Info

Publication number
JP6051164B2
JP6051164B2 JP2013541272A JP2013541272A JP6051164B2 JP 6051164 B2 JP6051164 B2 JP 6051164B2 JP 2013541272 A JP2013541272 A JP 2013541272A JP 2013541272 A JP2013541272 A JP 2013541272A JP 6051164 B2 JP6051164 B2 JP 6051164B2
Authority
JP
Japan
Prior art keywords
dextran
solution
colloid
blood
osmotic pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013541272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544265A (ja
JP2013544265A5 (enExample
Inventor
ステーン,スティグ
Original Assignee
エクスビボ パフュージョン アクチボラゲット
エクスビボ パフュージョン アクチボラゲット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクスビボ パフュージョン アクチボラゲット, エクスビボ パフュージョン アクチボラゲット filed Critical エクスビボ パフュージョン アクチボラゲット
Publication of JP2013544265A publication Critical patent/JP2013544265A/ja
Publication of JP2013544265A5 publication Critical patent/JP2013544265A5/ja
Application granted granted Critical
Publication of JP6051164B2 publication Critical patent/JP6051164B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/721Dextrans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
JP2013541272A 2010-11-30 2011-11-07 心肺バイパス用プライミング液 Active JP6051164B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1020300.8A GB201020300D0 (en) 2010-11-30 2010-11-30 Product
GB1020300.8 2010-11-30
PCT/EP2011/069524 WO2012072374A1 (en) 2010-11-30 2011-11-07 Priming solutions for cardiopulmonary bypass

Publications (3)

Publication Number Publication Date
JP2013544265A JP2013544265A (ja) 2013-12-12
JP2013544265A5 JP2013544265A5 (enExample) 2014-12-25
JP6051164B2 true JP6051164B2 (ja) 2016-12-27

Family

ID=43500877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541272A Active JP6051164B2 (ja) 2010-11-30 2011-11-07 心肺バイパス用プライミング液

Country Status (10)

Country Link
US (1) US8969323B2 (enExample)
EP (1) EP2646040B1 (enExample)
JP (1) JP6051164B2 (enExample)
CN (1) CN103228285B (enExample)
DK (1) DK2646040T3 (enExample)
ES (1) ES2575206T3 (enExample)
GB (1) GB201020300D0 (enExample)
PL (1) PL2646040T3 (enExample)
RU (1) RU2013127665A (enExample)
WO (1) WO2012072374A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110267534B (zh) 2017-01-17 2021-11-16 西维沃医疗科技有限公司 器官保存和/或灌注溶液
US11707600B2 (en) * 2020-11-18 2023-07-25 CardioDriven, Inc. Level set calibration and assurance for pulmonary artery pressure catheterization
CN117481629B (zh) * 2023-12-29 2024-03-26 成都水木医疗科技有限公司 一种多功能胶体渗透压仪及其测定方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1594697A (en) 1977-04-19 1981-08-05 Pharmacia Ab Oligosaccharide compositions for parenteral use
SE8900586L (sv) * 1989-02-21 1990-08-22 Pharmacia Ab Komposition och foerfarande foer att foerhindra adhesion mellan kroppsvaevnader
CN1102851C (zh) 1993-06-04 2003-03-12 生物时间公司 类血浆溶液
SE505499C2 (sv) * 1995-12-15 1997-09-08 Stiftelsen Facthor Förvaringslösning för organ och vävnad eller delar därav från människor och djur innehållande kalcium och nitroglycerin, användning därav samt förfarande för förvaring därmed
US6794124B2 (en) 1995-12-15 2004-09-21 Stiftelsen Facthor Preservation solution
US5902800A (en) * 1998-03-27 1999-05-11 Glenpharma Dextran formulations and method for treatment of inflammatory joint disorders

Also Published As

Publication number Publication date
PL2646040T3 (pl) 2017-04-28
CN103228285A (zh) 2013-07-31
US8969323B2 (en) 2015-03-03
EP2646040A1 (en) 2013-10-09
JP2013544265A (ja) 2013-12-12
US20130316977A1 (en) 2013-11-28
ES2575206T3 (es) 2016-06-27
EP2646040B1 (en) 2016-03-23
GB201020300D0 (en) 2011-01-12
DK2646040T3 (en) 2016-06-13
CN103228285B (zh) 2016-06-01
WO2012072374A1 (en) 2012-06-07
RU2013127665A (ru) 2015-01-10

Similar Documents

Publication Publication Date Title
Blumberg et al. 0.9% NaCl (normal saline)–perhaps not so normal after all?
Checchia et al. Nitric oxide delivery during cardiopulmonary bypass reduces postoperative morbidity in children—a randomized trial
AU2016276767B2 (en) Composition and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
JP2022500501A (ja) 血漿含有組成物
JP5823530B2 (ja) 危険にさらされた組織のオキシジェネーション増進方法
TWI554269B (zh) 用於治療自體消化之組成物
EP3551198A1 (en) Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
Medikonda et al. Trends and updates on cardiopulmonary bypass setup in pediatric cardiac surgery
JP6051164B2 (ja) 心肺バイパス用プライミング液
Kasper et al. Failure of autologous fresh frozen plasma to reduce blood loss and transfusion requirements in coronary artery bypass surgery.
Hasija et al. Bivalirudin anticoagulation in neonates and infants undergoing cardiac surgery
Morgan et al. Acid-base effects of a bicarbonate-balanced priming fluid during cardiopulmonary bypass: comparison with Plasma-Lyte 148. A randomised single-blinded study
Gertler et al. Cardiopulmonary bypass
Davis et al. Use of thromboelastograph and factor VII for the treatment of postoperative bleeding in a pediatric patient on ECMO after cardiac surgery
Vang et al. Clinical evaluation of poly (2-methoxyethylacrylate) in primary coronary artery bypass grafting
Oliver Jr et al. Heparin-coated versus uncoated extracorporeal circuit in patients undergoing coronary artery bypass graft surgery
Padalino et al. Modified ultrafiltration in pediatric heart surgery
Zarro et al. Albumin in the pump prime: its effect on postoperative weight gain
Pantaleon Fluid therapy in equine patients: small-volume fluid resuscitation
Morioka et al. The volume effect and safety of 6% hydroxyethyl starch 130/0.4 in patients undergoing major elective surgery: an uncontrolled, open-labeled, multi-center study
Mishra et al. A comparative study of Albumin versus 6% Hydroxyethyl starch used as priming solution for Cardiopulmonary Bypass in adults undergoing Coronary Artery Bypass Grafting
Vercueil et al. Resuscitation fluids in trauma, part II: which fluid should I give?
BRANCH PROSPECTIVE RANDOMISED COMPARATIVE STUDY OF EFFICACY OF COMBINATION OF TRANEXAMIC ACID AND ETHAMSYLATE BY ORAL AND INTRAVENOUS ROUTES IN RELATION TO CONTROL OF BLEEDING IN CARDIAC SURGERIES.
Draaisma Stepwise Improvement of Cardiopulmonary Bypass for Neonates and Infants
김재선 Efficacy, and safety of 6% hydroxyethyl starch 130/0.4 to albumin in post-operative patients following pancreaticoduodenectomy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161128

R150 Certificate of patent or registration of utility model

Ref document number: 6051164

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250